KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Purchased by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. raised its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 48.5% in the first quarter, Holdings Channel.com reports. The firm owned 111,106 shares of the specialty pharmaceutical company’s stock after buying an additional 36,279 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in KalVista Pharmaceuticals were worth $1,282,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in KalVista Pharmaceuticals by 567.3% during the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock worth $51,000 after buying an additional 3,767 shares during the last quarter. Aquatic Capital Management LLC bought a new position in KalVista Pharmaceuticals during the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC lifted its holdings in KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after buying an additional 5,502 shares during the last quarter. Legal & General Group Plc lifted its holdings in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock worth $69,000 after buying an additional 1,494 shares during the last quarter. Finally, Martin Worley Group bought a new position in KalVista Pharmaceuticals during the 4th quarter worth approximately $86,000.

KalVista Pharmaceuticals Stock Performance

Shares of NASDAQ:KALV opened at $14.36 on Friday. The stock has a market capitalization of $713.92 million, a price-to-earnings ratio of -3.95 and a beta of 0.05. The company has a 50 day moving average price of $12.07 and a 200 day moving average price of $10.60. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on KALV. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Finally, Jones Trading reissued a “buy” rating and issued a $30.00 price target on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals presently has an average rating of “Buy” and an average price target of $24.83.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Paul K. Audhya sold 2,776 shares of the firm’s stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $32,867.84. Following the completion of the sale, the insider now directly owns 106,611 shares in the company, valued at approximately $1,262,274.24. This trade represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 3,808 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $11.84, for a total transaction of $45,086.72. Following the completion of the sale, the chief executive officer now owns 293,367 shares of the company’s stock, valued at $3,473,465.28. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 8,730 shares of company stock valued at $102,226 over the last ninety days. Corporate insiders own 10.50% of the company’s stock.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).